Investigation for Clinical Efficacy and Safety of Ipragliflozin 50mg and 100mg on Type II Diabetes
Status:
Completed
Trial end date:
2018-02-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate clinical efficacy and safety of Sodium Glucose
Co-transporter 2 (SGLT2) inhibitor, ipragliflozin, at doses of 50mg and 100mg, for Type II
Diabetes under usual care. It is also to investigate and analyze the exploratory influential
factor of ipragliflozin treatment on clinical efficacy and safety.
Details
Lead Sponsor:
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan Translational Research Informatics Center, Kobe, Hyogo, Japan